


Fig. 1



**** Two-way ANOVA, Tukey Test $p < 0.0001$

CVA21-encoding RNA formulated with Lipofectamine (positive control)

CVA21 LNP formulation # 70032-6.C

Fig. 2A




Fig. 2B




Fig. 3





Fig. 4



6/114



Fig. 5B**Fig. 5A**

Fig. 6B





Fig. 6A



PWD: 22454536

Fig. 6C

P2 Motif					
DSM36	(SEQ ID NO:24)	AAACTCGTCTGAGCGAGTATAAACAGGTCATTAAAGCTCAGAGCGTTCACCGGGATCATTC	60		
M1	(SEQ ID NO:23)	AAACTCGTCTGAGCGAGTATAAACAGGTCATTAAAGCTCAGAGCGTTCACCGGGATCATGC	60		
Pistol	(SEQ ID NO:16)	GGACTCGTCTGAGCGAGTATAAACAGGTCATTAAAGCTCAGAGCGTTCACCGGGGAAATTC	60		
PP-G	(SEQ ID NO:19)	GGACTCGTCTGAGCGAGTATAAACAGTGTTTTAAAGCTCAGAGCGTTCACCGGGGAAATTC	60		
PP	(SEQ ID NO:17)	GGACTCGTCTGAGCGAGTATAAACAGTTTATTAAAGCTCAGAGCGTTCACCGGGGAAATTC	60		
PP-T	(SEQ ID NO:18)	GGACTCGTCTGAGCGAGTATAAACAGTTTTTTTAAAGCTCAGAGCGTTCACCGGGGAAATTC	60		
		***** * ***** ** *			
DSM36	(SEQ ID NO:24)	GGTGAGG	67		
M1	(SEQ ID NO:23)	GGTGAGG	67		
Pistol	(SEQ ID NO:16)	GGTGAGG	67		
PP-G	(SEQ ID NO:19)	GGTGAGG	67		
PP	(SEQ ID NO:17)	GGTGAGG	67		
PP-T	(SEQ ID NO:18)	GGTGAGG	67		

Fig. 7A




Fig. 7B




Fig. 8A




Fig. 8B




Fig. 8C




Fig. 8D




Fig. 8E




Fig. 9




Fig. 10




Fig. 11A





Fig. 11B






Fig. 12A

Fig. 12B






Fig. 13



22/114

NSCLC
KY V EF



Lung
KY V EF




Fig. 14




Fig. 15A




Fig. 15B

Pancreas
KY v EF





Fig. 15C

Fig. 16A



27/114

Fig. 16B





Fig. 16C



In the single SCC line EF is better by 56-fold

Fig. 17A




Fig. 17B




Fig. 17C




Fig. 17D




Fig. 17E




Fig. 18A




Fig. 18B





Fig. 18C



↑ Median IC50

Fig. 19

hICAM1 Cell line	TCID50s	
	KY	EF
CT26 WT	21.80	6.89
CT26 IFNARKO A-8	15.67	0.34
4T1	17.62	0.09
EMT6	19.66	1.11
B16-F10	0.01	0.01
A20	>30	6.30
CT2A	13.11	5.76
M109	1.27	1.22

Fig. 20A




Fig. 20B




Fig. 21




Fig. 22




Fig. 23




Fig. 24




Fig. 25A




Fig. 25B




Fig. 25C




Fig. 26




Fig. 27A




Fig. 27B




Fig. 27C




Fig. 28A




Fig. 28B




Fig. 29A





Fig. 29B






Fig. 30

Fig. 31A







Fig. 31B

H1299 Tumor Size

CVA21 EF 30pA + SEQ ID NO: 17 ribozyme CVA21 EF 70pA + SEQ ID NO: 17 ribozyme



CVA21 EF 30pA + SEQ ID NO: 18 ribozyme



CVA21 EF 70pA + SEQ ID NO: 18 ribozyme




Fig. 32




Fig. 33




Fig. 34




Fig. 35




Fig. 36




Fig. 37




Fig. 38A




Fig. 38B




Fig. 39A





Fig. 39B








Fig. 39D



66/114

Fig. 40A



67/114

Fig. 40B




Fig. 41




Fig. 42





Fig. 43






Fig. 44

Fig. 45




Fig. 46A




Fig. 46B



Fig. 47A




Fig. 47B




Fig. 48




Fig. 49A




Fig. 49C




Fig. 49B




Fig. 49D




Fig. 49E




Fig. 49G





Fig. 49F






Fig. 50

Fig. 51





Fig. 52A

NCI-H446 Tumor Model



↑ IV dose 0.2 mpk on day 1, 8.

Fig. 52B




Fig. 53A




Fig. 53B




Fig. 54A

UV A280 Absorption of CVA21 Viral Genome with
Varying Poly-A Tail Length on Oligo-dT Chromatography




Fig. 54B
UV A280 Absorption of SW Viral Genome with
Varying Poly-A Tail Length on Oligo-dT Chromatography




Fig. 55A




Fig. 55B




Fig. 55C




Fig. 56A




Fig. 56B




Fig. 56C




Fig. 57




Fig. 58A

SVV-nLuc Bioluminescence
96 hours post-IV treatment





Fig. 58B

SVV-nLuc Bioluminescence
96 hours post-IV treatment






Fig. 58C

Fig. 58E




Fig. 58D




Fig. 58F




Fig. 59A




Fig. 59B




Fig. 59C





Fig. 59D



100/114




Fig. 59E

Fig. 60A




Fig. 60B




Fig. 61B




Fig. 61D




Fig. 61A




Fig. 61C




Fig. 62B




Fig. 62A




Fig. 62C




Fig. 62E




Fig. 62D




Fig. 62F




Fig. 63B




Fig. 63A




Fig. 63C




Fig. 63E

CAT11/Brij




Fig. 63D

CAT11/DMG




Fig. 64A





Fig. 64B



110/114

Fig. 65A




Fig. 65B




Fig. 66B





Fig. 66A






Fig. 67




Fig. 68

